US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer.

Oladimeji Akinboro,Nicole Drezner,Anup Amatya,Jin Runyan, Jeanne Fourie-Zirkelbach,Miao Zhao,Youwei Bi,Kwadwo Korsah,Bronwyn Mixter,Shenghui Tang,Erin Larkins,Richard Pazdur,Julia A Beaver,Harpreet Singh

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 2|浏览11

暂无评分

摘要

This approval, the first for any regimen for the neoadjuvant treatment of NSCLC in the United States, was supported by a statistically significant and clinically meaningful improvement in EFS with no evidence of detriment in OS or negative impact on patients' receipt and timing of surgery or surgical outcomes.

查看译文

关键词

non–small-cell non–small-cell lung cancer,lung cancer,chemotherapy,platinum-doublet

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要